Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tivumecirnon - RAPT Therapeutics

Next Previous
Drug Profile

Tivumecirnon - RAPT Therapeutics

Alternative Names: FLX-475

Latest Information Update: 11 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FLX Bio
  • Developer Hanmi Pharmaceutical; Merck & Co; RAPT Therapeutics
  • Class 2 ring heterocyclic compounds; Antineoplastics; Azetidines; Piperidines; Pyrazines; Pyrazoles; Small molecules
  • Mechanism of Action CCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cancer; Gastric cancer; Malignant melanoma

Most Recent Events

  • 24 Apr 2025 Tivumecirnon - RAPT Therapeutics is available for licensing worldwide (excluding South Korea, China, Hong Kong, Macau, Taiwan) as of 24 Apr 2025. https://rapt.com/about-us/#contact
  • 08 Mar 2025 Final adverse events and efficacy data from a phase-II trial in Gastric cancer released by Hanmi Pharmaceutical
  • 31 Jan 2025 RAPT Therapeutics completes the phase I/II trial for Cancer (Late-stage disease, Monotherapy, Combination therapy, Metastatic disease) in USA, Australia, Hong Kong, South Korea, Taiwan and Thailand (PO) (NCT03674567)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top